IP Library Granted Patent US 8,545,487
Granted Patent B2
US 8,545,487 · App. 12/315,829 · Granted Oct 1, 2013

Eye therapy system

Inventors: David Muller (Boston, MA); Thomas Ryan (Waltham, MA)
Assignee: Avedro Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,545,487
App. No.
12/315,829
Granted
Oct 1, 2013
Kind
B2
Abstract

Heat is generated in corneal fibrils in a cornea of an eye according to a selected pattern. The heat causes the corneal fibrils corresponding to the selected pattern to transition from a first structure to a second structure. The second structure provides a desired reshaping of the cornea. A cross-linking agent is then activated in the region of corneal fibrils according to the selected pattern. The cross-linking agent prevents the corneal fibrils from changing from the second structure. Thus, embodiments stabilize corneal tissue and improve its biomechanical strength after desired structural changes have been achieved in the corneal tissue. Accordingly, the embodiments help to preserve the desired reshaping of the cornea.

Claims (15)

1. A method for applying therapy to an eye, comprising:

generating heat to corneal fibrils in a cornea of an eye according to a selected pattern, the heat causing the corneal fibrils corresponding to the selected pattern to transition from a first structure to a second structure, the second structure providing a reshaping of the cornea; and

activating a cross-linking agent in the region of corneal fibrils according to the selected pattern, the cross-linking agent preventing the corneal fibrils from changing from the second structure.

2. The method according to claim 1 , further comprising applying the cross-linking agent in the region of corneal fibrils according to the selected pattern.

3. The method according to claim 2 , wherein applying the cross-linking agent according to the selected pattern comprises removing corneal epithelium according to the selected pattern and applying the cross-linking agent directly to the region of corneal fibrils below the epithelium.

4. The method according to claim 3 , wherein the initiating element comprises ultraviolet light.

5. The method according to claim 3 , wherein applying the initiating element according to the selected pattern comprises applying a mask, the mask limiting application of the initiating element according to the selected pattern.

6. The method according to claim 3 , wherein applying the initiating element according to the selected pattern comprises applying at least one optical device, the at least one optical device directing the initiating element to the eye according to the selected pattern.

7. The method according to claim 3 , wherein the cross-linking agent is Riboflavin.

8. The method according to claim 1 , wherein activating the cross-linking agent according to the selected pattern comprises applying an initiating element to the region of the corneal fibrils according to the selected pattern, the initiating element activating the cross-linking agent.

9. The method according to claim 1 , further comprising before the step of generating the heat, applying the cross-linking agent in the region of corneal fibrils.

10. The method according to claim 1 , further comprising applying heat-sensitive liposomes containing the cross-linking agent to the region of corneal fibrils.

11. The method according to claim 1 , wherein the step of applying the heat-sensitive liposomes occurs before the step of generating the heat, the heat causing release of the cross-linking agent from the heat-sensitive liposomes.

12. The method according to claim 1 , wherein the cross-linking agent comprises at least one of fibril associated collagens with interrupted triple helices (FACIT collagens) and leucine-rich repeat (LRR) proteoglycans.

13. The method according to claim 1 , wherein the cross-linking agent is in an ophthalmic solution or an ophthalmic ointment.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2019
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: AVEDRO, INC.
Reel/Frame 051080/0756 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NO. 14/140,184 PREVIOUSLY RECORDED AT REEL: 042167 FRAME: 0671. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 1, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042390/0659 →
SECURITY INTEREST Recorded Apr 27, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042167/0671 →
SECURITY AGREEMENT Recorded Feb 13, 2012
From: AVEDRO, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 027697/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2009
From: MULLER, DAVID; RYAN, THOMAS
To: AVEDRO, INC.
Reel/Frame 022304/0333 →
Continuity (4)
Provisional Application 60992486 · Dec 5, 2007
Provisional Application 61098489 · Sep 19, 2008
Provisional Application 61101509 · Sep 30, 2008
Related Publication 20090149842A1 · Jun 11, 2009